Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H39F3N12O7 |
InChIKeyYXSXFMHKDNIZFS-UHFFFAOYSA-N |
CAS Registry2360533-90-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 29 Dec 2020 |